Sanofi (NASDAQ:SNY) Shares Gap Up – Should You Buy?

Sanofi (NASDAQ:SNY) shares gapped up prior to trading on Friday . The stock had previously closed at $52.05, but opened at $53.90. Sanofi shares last traded at $53.57, with a volume of 697,275 shares trading hands.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on SNY shares. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Argus increased their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The stock has a market cap of $137.00 billion, a PE ratio of 28.29, a P/E/G ratio of 1.40 and a beta of 0.60. The firm’s 50-day moving average is $56.08 and its 200 day moving average is $51.67.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.95 earnings per share. As a group, research analysts anticipate that Sanofi will post 4.23 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Fifth Third Wealth Advisors LLC acquired a new position in Sanofi in the 1st quarter valued at $410,000. Register Financial Advisors LLC acquired a new stake in Sanofi in the first quarter valued at about $29,000. First Bank & Trust boosted its holdings in Sanofi by 24.1% in the 1st quarter. First Bank & Trust now owns 35,855 shares of the company’s stock valued at $1,743,000 after purchasing an additional 6,968 shares in the last quarter. BKM Wealth Management LLC increased its position in Sanofi by 74.3% during the 1st quarter. BKM Wealth Management LLC now owns 8,314 shares of the company’s stock worth $404,000 after purchasing an additional 3,543 shares during the period. Finally, Park Place Capital Corp raised its stake in shares of Sanofi by 6.3% during the 1st quarter. Park Place Capital Corp now owns 9,068 shares of the company’s stock worth $441,000 after buying an additional 534 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.